Catalyst Dossier · compiled by CeliA 🧫
Jazz Pharmaceuticals plc (JAZZ)
Pharmaceutical Preparations · market cap $14.1B · as of 2026-07-11
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-09-09
Conference
Pipeline
20
programs
Upcoming events
2
next 90d+
Dossier
Ready
cached
Jazz Pharmaceuticals plc (JAZZ) is a Dublin-headquartered global biopharmaceutical company focused on oncology and neuroscience, with ~$4.3B in 2025 revenue and a market cap of ~$15.5B. The company carries a substantial net debt load of ~$4.5B against $1.8B in cash, and operates a broad pipeline spanning cannabinoid-based therapies, sodium oxybate franchises, and oncology assets including zanidatamab and dordaviprone (ONC201). Near-term catalysts include Phase 3 readouts for capecitabine (gastric) and dordaviprone (H3 K27M glioma) by mid-to-late summer 2026.
The catalyst path
- 2026-09-09Conferenceimp 2/10
- 2026-12-01 (est.)Phase 2 · Lurbinectedinimp 7/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Sativex | Phase 3 | Multiple Sclerosis |
| Nabiximols | Phase 3 | Pain |
| Suvecaltamide | Phase 2 | Parkinson Disease |
| Sativex® | Phase 3 | Spasticity |
| GWP42003-P | Phase 3 | Epilepsy |
| GWP42003-P 20 mg/kg/day Dose | Phase 3 | Epilepsy |
| Xyrem | Phase 3 | Narcolepsy With Cataplexy |
| Lurbinectedin | Phase 2 | Refractory Ewing Sarcoma |
| GWP42006 | Phase 2 | Epilepsy |
| ZW25 (Zanidatamab) | Phase 2 | HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer |
| GWP42003 | Phase 2 | Schizophrenia |
| Evorpacept | Phase 2 | HER2-expressing Cancers |
| JZP-110 | Phase 3 | Obstructive Sleep Apnea |
| Brincidofovir | Phase 3 | Adenovirus Infection |
| GWP42004 | Phase 2 | Dyslipidemias |
| Xyrem® | Phase 3 | Fibromyalgia |
| JZP385 | Phase 2 | Essential Tremor |
| Dordaviprone (ONC201) | Phase 3 | H3 K27M |
| Sodium Oxybate | Phase 3 | Essential Tremor |
| IM JZP-458 | Phase 3 | Acute Lymphoblastic Leukemia |
Price & technical context
3-month
+4.9%
6-month
+26.7%
12-month
+100.3%
52-wk range
$125.22–$261.62
vs 50-day MA
+1.3%
vs 200-day MA
+23.5%
Realized vol
49.9%
Max drawdown
-32.2%
Daily closes through 2026-08-26. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for JAZZ (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.